TrialPath

Find a study

Match me to a study

131 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

112 studies on the map

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoStudy of ALTO-300 in MDD — Site 200, PhoenixStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — Arizona Liver Health - Chandler, ChandlerZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, PheonixA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghImaging Depression in Parkinson's Disease — Yale University, New HavenAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GrovePsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisLeucine in Midlife Depression — Emory University Hospital, AtlantaPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaJAK Signaling in Depression — Emory University, AtlantaModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkSleep to Reduce Incident Depression Effectively in Peripartum — Henry Ford Medical Center, NoviLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsSodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) — NYU Langone Health, New YorkRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesMindfulness Engaged Neurostimulation for Depression (MEND II) — UC San Diego Health Psychiatry, San DiegoCannabidiol for Reduction of Brain Neuroinflammation — Massachusetts General Hospital, BostonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, ColumbusPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattlePsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, Boulder5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonSleep Health in U.S. Marines — San Diego State University, San DiegoA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaA Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients — Mayo Clinic Florida, JacksonvilleStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaInvestigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults — Southwest Autism Research and Resource Center, PhoenixUse of CBD in the Treatment of Anxiety — University of Florida, GainesvilleStudy of Dextromethorphan in OCD and Related Disorders — Stanford University, StanfordGaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety — National Institutes of Health Clinical Center, BethesdaEvaluating Buspirone to Treat Opioid Withdrawal — Kahlert Institute for Addictino Medicin, Baltimore